These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17407483)

  • 21. Flecainide in the intrauterine treatment of fetal supraventricular tachycardia.
    Krapp M; Baschat AA; Gembruch U; Geipel A; Germer U
    Ultrasound Obstet Gynecol; 2002 Feb; 19(2):158-64. PubMed ID: 11876808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of flecainide for refractory atrial tachycardia of pregnancy.
    Ahmed K; Issawi I; Peddireddy R
    Am J Crit Care; 1996 Jul; 5(4):306-8. PubMed ID: 8811156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of maternal flecainide concentration in management of fetal supraventricular tachycardia: a step in the right direction.
    Cuneo BF; Benson DW
    Heart Rhythm; 2014 Nov; 11(11):2054-5. PubMed ID: 25128734
    [No Abstract]   [Full Text] [Related]  

  • 24. Assessment of serum flecainide trough levels in patients with tachyarrhythmia.
    Homma M; Kuga K; Doki K; Katori K; Yamaguchi I; Sugibayashi K; Kohda Y
    J Pharm Pharmacol; 2005 Jan; 57(1):47-51. PubMed ID: 15638992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transplacental flecainide therapy in the treatment of fetal supraventricular tachycardia.
    D'Souza D; MacKenzie WE; Martin WL
    J Obstet Gynaecol; 2002 May; 22(3):320-2. PubMed ID: 12521516
    [No Abstract]   [Full Text] [Related]  

  • 26. ECGs in the ED.
    Tanel RE
    Pediatr Emerg Care; 2008 Nov; 24(11):803-4. PubMed ID: 19018229
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug therapy: flecainide and tocainide.
    N Engl J Med; 1987 Feb; 316(6):343-5. PubMed ID: 3100952
    [No Abstract]   [Full Text] [Related]  

  • 28. Nadolol for Treatment of Supraventricular Tachycardia in Infants and Young Children.
    von Alvensleben JC; LaPage MJ; Caruthers R; Bradley DJ
    Pediatr Cardiol; 2017 Mar; 38(3):525-530. PubMed ID: 27995288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flecainide and amiodarone: combined therapy for refractory tachyarrhythmias in infancy.
    Fenrich AL; Perry JC; Friedman RA
    J Am Coll Cardiol; 1995 Apr; 25(5):1195-8. PubMed ID: 7897134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sudden death of a horse with supraventricular tachycardia following oral administration of flecainide acetate.
    Dembek KA; Hurcombe SD; Schober KE; Toribio RE
    J Vet Emerg Crit Care (San Antonio); 2014; 24(6):759-63. PubMed ID: 25388866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of junctional tachycardia with high doses of flecainide in infants].
    Chantepie A; Moquet B; Cosnay P; Blanchard P; Marchand S; Grenier B; Fauchier JP
    Presse Med; 1988 Sep; 17(31):1587-8. PubMed ID: 2971964
    [No Abstract]   [Full Text] [Related]  

  • 32. [Flecainide and paroxysmal supraventricular tachycardia in the operating room].
    Borgeat A; Thorin D
    Schweiz Med Wochenschr; 1988 Jun; 118(24):944-6. PubMed ID: 3135590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arrhythmogenic right ventricular dysplasia: pregnancy under flecainide treatment.
    Villanova C; Muriago M; Nava F
    G Ital Cardiol; 1998 Jun; 28(6):691-3. PubMed ID: 9672783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paranoid psychosis and myoclonus: flecainide toxicity in renal failure.
    Ting SM; Lee D; Maclean D; Sheerin NS
    Cardiology; 2008; 111(2):83-6. PubMed ID: 18376118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. β1-Adrenergic receptor Arg389Gly polymorphism affects the antiarrhythmic efficacy of flecainide in patients with coadministration of β-blockers.
    Doki K; Sekiguchi Y; Kuga K; Aonuma K; Homma M
    Pharmacogenet Genomics; 2016 Oct; 26(10):481-5. PubMed ID: 27500822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma concentrations of flecainide acetate, a new antiarrhythmic agent, in humans.
    Conard GJ; Carlson GL; Frost JW; Ober RE; Leon AS; Hunninghake DB
    Clin Ther; 1984; 6(5):643-52. PubMed ID: 6478470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SCN5A promoter haplotype affects the therapeutic range for serum flecainide concentration in Asian patients.
    Doki K; Homma M; Kuga K; Aonuma K; Kohda Y
    Pharmacogenet Genomics; 2013 Jul; 23(7):349-54. PubMed ID: 23635804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffuse infiltrative lung disease associated with flecainide. Report of two cases.
    Pesenti S; Lauque D; Daste G; Boulay V; Pujazon MC; Carles P
    Respiration; 2002; 69(2):182-5. PubMed ID: 11961436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics.
    Till JA; Shinebourne EA; Rowland E; Ward DE; Bhamra R; Haga P; Johnston A; Holt DW
    Br Heart J; 1989 Aug; 62(2):133-9. PubMed ID: 2504263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between plasma concentrations and suppression of ventricular extrasystoles by flecainide acetate (R-818), a new antiarrhythmic, in patients.
    Conard GJ; Cronheim GE; Klempt HW
    Arzneimittelforschung; 1982; 32(2):155-9. PubMed ID: 7199921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.